Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure.

Author: FukuokaHidetada, HoshidaShiro, InoueSoki, InuiHirooki, MinamisakaTomoko, MineKentaro, ShinodaYukinori, TachibanaKoichi, UedaKumpei, UenoKeisuke

Paper Details 
Original Abstract of the Article :
BACKGROUNDS: Tolvaptan significantly increases urine volume in acute decompensated heart failure (ADHF); serum sodium level increases due to aquaresis in almost all cases. We aimed to elucidate clinical factors associated with hypernatremia in ADHF patients treated with tolvaptan. METHODS: We enrol...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597047/

データ提供:米国国立医学図書館(NLM)

Tolvaptan-Induced Hypernatremia: Exploring the Role of Low Serum Potassium

This study investigates the clinical factors associated with tolvaptan-induced hypernatremia, a potential side effect of this medication used for treating acute decompensated heart failure (ADHF). The researchers analyzed the clinical characteristics of 117 ADHF patients treated with tolvaptan, focusing on the relationship between low serum potassium levels and the development of hypernatremia. This study uses a retrospective observational design to explore the association between low serum potassium and tolvaptan-induced hypernatremia.

Low Serum Potassium: A Potential Risk Factor for Hypernatremia

The study suggests that low serum potassium levels may be a significant risk factor for the development of tolvaptan-induced hypernatremia in ADHF patients. The research highlights the importance of monitoring serum potassium levels in patients receiving tolvaptan, particularly those with lower potassium levels. This research emphasizes the need for careful monitoring and management of serum potassium levels during tolvaptan treatment to mitigate the risk of hypernatremia.

Tolvaptan: Balancing Benefits and Risks

This study underscores the importance of balancing the potential benefits of tolvaptan in treating ADHF with the potential risks associated with its use. It emphasizes the need for careful patient selection, ongoing monitoring, and prompt intervention to manage any adverse events. This research encourages a balanced approach to the use of tolvaptan, recognizing the importance of individualizing treatment strategies and ensuring patient safety.

Dr. Camel's Conclusion

This study is like a camel caravan traversing a dry and unforgiving desert of ADHF, where tolvaptan can be a valuable resource but requires careful navigation. It reminds us that while tolvaptan can be a helpful treatment, it’s crucial to monitor for potential side effects and adjust treatment strategies accordingly.

Date :
  1. Date Completed 2021-02-01
  2. Date Revised 2021-02-01
Further Info :

Pubmed ID

33121430

DOI: Digital Object Identifier

PMC7597047

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.